A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia
Blood (2022) 140 (Supplement 1): 1453–1455.
Currently there are no citedby results. Try again later.
